VERAXA Biotech AG (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC T-cell engager (BiTAC-TCE) program through a collaboration with ATUM, which will apply its Leap-In Transposase technology to generate stable clonal cell lines. This effort supports IND/CTA-enabling activities and future clinical development, following encouraging preclinical data presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting.
The collaboration is intended to advance CMC development, including early process, analytical and formulation development, as well as the production of material for nonclinical studies. VERAXA's BiTAC-TCE platform is designed to improve tumor selectivity by splitting the T-cell engager into two complementary precursors that activate only when both bind separate tumor targets on the same cell. The company believes this conditional "AND"-gated approach could reduce off-tumor toxicity associated with conventional T-cell engagers while maintaining anti-cancer activity, potentially enabling higher dosing and a broader therapeutic window.
For industry leaders, this development underscores a significant shift toward precision immunotherapy. Traditional T-cell engagers, while effective, often cause severe side effects due to activation in healthy tissues. VERAXA's approach could address a critical bottleneck in oncology: balancing efficacy with safety. If successful, this technology may expand the treatable patient population and improve outcomes for cancers with high unmet need.
The use of ATUM's Leap-In Transposase technology for cell line development is notable for its ability to generate high-yielding, stable clones more rapidly than traditional methods, potentially accelerating timelines to clinic. This is particularly important in the competitive biotech landscape where speed to market can determine a therapy's commercial viability.
VERAXA, founded on scientific breakthroughs at the European Molecular Biology Laboratory (EMBL), is building a pipeline of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. The company's proprietary BiTAC platform is a registered trademark of VERAXA Biotech GmbH.
Investors can find the latest news and updates relating to VRXA in the company’s newsroom at http://ibn.fm/VRXA. The full press release is available at https://ibn.fm/FCIlk.
